Pharmacokinetics and bioavailability studies of generic ondansetron, and the innovator preparation, in healthy Thai male volunteers.
Artículo
en Inglés
| IMSEAR
| ID: sea-41072
ABSTRACT
The pharmacokinetics and bioequivalence of two oral formulations of ondansetron were evaluated; Zetron (Biolab Pharmaceutical, Bangkok, Thailand), as the test formulation and Zofran (Glaxo Wellcome Operations, Greenford, UK), as the reference formulation. The two products were administered as a single oral dose of 8 mg according to a randomized two-way crossover design to 12 healthy Thai male volunteers. The washout period between treatment was 1 week. Ondansetron plasma concentrations were measured using HPLC. The oral bioavailability of ondansetron averaged 67 per cent and the elimination half-life after oral administration was 5.6 hours. The means and parametric 90 per cent CI of the ratios of Cmax and AUC 0-alpha [mu Zetron (Test)/mu Zofran (Reference)] were 0.95 (0.84-1.07) and 0.94 (0.80-1.10), respectively. These values were well within the bioequivalence range of 0.8-1.25 as established by the US-FDA. The mean difference of Tmax (Test-Reference) was approximately 20 per cent. Thus, our study demonstrated bioequivalence of the two products (Zetron and Zofran) regarding the rate and extent of absorption.
Texto completo:
Disponible
Índice:
IMSEAR (Asia Sudoriental)
Asunto principal:
Valores de Referencia
/
Tailandia
/
Humanos
/
Masculino
/
Disponibilidad Biológica
/
Química Farmacéutica
/
Sensibilidad y Especificidad
/
Adolescente
/
Medicamentos Genéricos
/
Ondansetrón
Tipo de estudio:
Ensayo Clínico Controlado
/
Estudio diagnóstico
/
Estudio pronóstico
País/Región como asunto:
Asia
Idioma:
Inglés
Año:
1999
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS